Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | QPCT | Q16769 | 7/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 2/20 | 0.40 |
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | PRKCI | P41743 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.36 |
| ▸ | WNT3A | P56704 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11476242 | 0.85 | ADRB2 (0.52) | POLBMAPK1KDM4EMAPTKMT2A | |
| SCHEMBL24630978 | 0.85 | ADRB2 (0.52) | POLBMAPK1KDM4EMAPTKMT2A | |
| SCHEMBL10467019 | 0.78 | PRKCI (0.51) | HTTQPCTMAPK1NAMPTMMP12 | |
| SCHEMBL24631002 | 0.78 | HTT (0.41) | HTTPOLBMAPK1PRKCIKDM4E | |
| SCHEMBL10465746 | 0.77 | PRKCI (0.46) | HTTQPCTPOLBNAMPTMMP12 | |
| SCHEMBL10467043 | 0.77 | PRKCI (0.46) | HTTQPCTPOLBMAPK1NAMPT | |
| SCHEMBL24631003 | 0.76 | EPHX1 (0.49) | QPCTPOLBMAPK1HDAC6PRKCI | |
| SCHEMBL23655003 | 0.74 | PRKCI (0.53) | HTTQPCTNAMPTMMP12HDAC6 | |
| SCHEMBL8013060 | 0.74 | PRKCI (0.53) | HTTQPCTNAMPTMMP12HDAC6 | |
| SCHEMBL11476231 | 0.74 | ADRB2 (0.52) | POLBMAPK1KDM4EMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220315534-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. | 2022-10-06 | — | — | US | disclosed |
| WO-2021003161-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315534-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | ADRB2, ADRB1, ADRA2C | HTT 3293/4885QPCT 2130/4885POLB 1438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.